Results 151 to 160 of about 4,098 (181)

Prognostic factors for thyroid-stimulating immunoglobulin normalization in moderate-to-severe Graves' orbitopathy: a 36-month longitudinal study. [PDF]

BMC Ophthalmol
Park J, Son Y, Kim J, Kim S, Choi HY.
europepmc   +1 more source

How Age Affects Graves' Orbitopathy-A Tertiary Center Study. [PDF]

J Clin Med
Oeverhaus M, Sander J, Smetana N, Bechrakis NE, Inga N, Al-Ghazzawi K, Chen Y, Eckstein A.   +7 more
europepmc   +1 more source

Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy. [PDF]

Nucl Med Commun
Quah NQX, Sobti MM, Wren AM, Scawn R, Kalogianni E, Cleland J, Maenhout A.   +6 more
europepmc   +1 more source

Clinical performance of a novel and rapid bioassay for detection of thyroid-stimulating immunoglobulins in Graves' orbitopathy patients: a comparison with two commonly used immunoassays. [PDF]

Front Endocrinol (Lausanne)
Hötte GJ, de Bie M, de Keizer ROB, Kolijn PM, Drexhage RC, Veenbergen S, Versnel MA, van Hagen PM, Paridaens D, Dik WA.   +9 more
europepmc   +1 more source

Correlation between Structural and Functional Changes in Patients with Raised Intraocular Pressure Due to Graves' Orbitopathy. [PDF]

Diagnostics (Basel)
Bagatin F, Prpić A, Škunca Herman J, Zrinšćak O, Iveković R, Vatavuk Z.   +5 more
europepmc   +1 more source

Temporal trends in the clinical presentation of Graves' orbitopathy: a single-center retrospective study. [PDF]

J Endocrinol Invest
Le Moli R, Naselli A, Giudice FL, Costanzo G, Frasca F, Belfiore A.   +5 more
europepmc   +1 more source

Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy. [PDF]

Ophthalmol Ther
Yu Y, Hu YX, Lu MX, Ouyang ZL, Xu MT, Zhao LY, Wang M.   +6 more
europepmc   +1 more source

TMEM2 inhibits the development of Graves' orbitopathy through the JAK-STAT signaling pathway. [PDF]

J Biol Chem
Li H, Min J, Yang Y, Suo W, Wang W, Tian J, Qin Y.   +6 more
europepmc   +1 more source

Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience. [PDF]

Pharmacol Rep
Sawicka-Gutaj N, Gruszczyński D, Zawalna N, Nijakowski K, Skiba A, Pochylski M, Sowiński J, Ruchała M.   +7 more
europepmc   +1 more source

Determinants of clinical outcome in patients with moderate/severe Graves' orbitopathy undergoing treatment with parenteral glucocorticoids: a retrospective study. [PDF]

Front Endocrinol (Lausanne)
Le Moli R, Naselli A, Costanzo G, Piticchio T, Tumino D, Pellegriti G, Frasca F, Belfiore A.   +7 more
europepmc   +1 more source